DOI QR코드

DOI QR Code

Clinicopathological Features of Patients with Malignant Mesothelioma in a Multicenter, Case-Control Study: No Role for ABO-Rh Blood Groups

  • Utkan, Gungor (Department of Medical Oncology, Ankara University School of Medicine) ;
  • Urun, Yuksel (Department of Medical Oncology, Ankara University School of Medicine) ;
  • Cangir, Ayten Kayi (Department of Thoracic Surgery, Ankara University School of Medicine) ;
  • Kilic, Dalokay (Department of Thoracic Surgery, Baskent University School of Medicine) ;
  • Ozdemir, Nuriye Yildirim (Medical Oncology Clinic, Ankara Numune Research and Educational Hospital) ;
  • Oztuna, Derya Gokmen (Department of Biostatistics, Ankara University School of Medicine) ;
  • Bulut, Erhan (Department of Thoracic Surgery, Ankara University School of Medicine) ;
  • Arslan, Ulku Yalcintas (Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, Medical Oncology Clinic) ;
  • Kocer, Murat (Department of Medical Oncology, Suleyman Demirel University School of Medicine) ;
  • Kavukcu, Sevket (Department of Thoracic Surgery, Ankara University School of Medicine) ;
  • Icli, Fikri (Department of Medical Oncology, Ankara University School of Medicine)
  • Published : 2013.01.31

Abstract

Background: Malignant mesothelioma (MM) is an aggressive tumor of mesothelial surfaces. Previous studies have observed an association between ABO blood groups and risk of certain malignancies, including pancreatic and gastric cancer; however, no information on any association with MM risk is available. The aim of this study was to investigate possible associations amoong MM clinicopathological features and ABO blood groups and Rh factor. Materials and Methods: In 252 patients with MM, the ABO blood group and Rh factor were examined and compared with the control group of 3,022,883 healthy volunteer blood donors of Turkish Red Crescent between 2004 and 2011. The relationship of blood groups with various clinicopathological features were also evaluated in the patient group. Results: The median age was 55 (range: 27-86) and 61.5% of patients were male. While 82.8% of patients had a history of exposure to asbestos, 60.7% of patients had a smoking history. Epithelioid (65.1%) was the most common histology and 18.7% of patients had mixed histology. Overall, the ABO blood group distribution of the 252 patients with MM was comparable with the general population. The median overall survival (OS) was 14 months (95% confidence interval, 11.3-16.6 months). The median OS for A, B, AB, and O were 11, 15, 16, and 15 months respectively (p=0.396). First line chemotherapy was administered to 118 patients. The median OS of patients on pemetrexed or gemcitabine was longer than patient who was not administered chemotherapy [17 months (95%CI, 11.7-22.2) vs. 9 months (95%CI, 6.9-11.0); p<0.001]. Conclusions: The results of this study suggest that patients with MM can benefit from treatment with pemetrexed or gemcitabine in combination with cisplatin. We did not observe a statistically significant association between ABO blood group and risk of MM.

References

  1. Urun Y, Ozdemir NY, Utkan G, et al (2012). ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma. Asian Pac J Cancer Prev, 13, 6097-100. https://doi.org/10.7314/APJCP.2012.13.12.6097
  2. van der Bij S, Schaake E, Koffijberg H, et al (2011). Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer, 104, 1325-33. https://doi.org/10.1038/bjc.2011.104
  3. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P (2011). Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol, 78, 92-111. https://doi.org/10.1016/j.critrevonc.2010.04.004
  4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44. https://doi.org/10.1200/JCO.2003.11.136
  5. Wolpin BM, Chan AT, Hartge P, et al (2009). ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101, 424-31. https://doi.org/10.1093/jnci/djp020
  6. Kao SC, Reid G, van Zandwijk N, Henderson DW, Klebe S (2011). Molecular biomarkers in malignant mesothelioma: state of the art. Pathology, 43, 201-12. https://doi.org/10.1097/PAT.0b013e3283445e67
  7. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Statistical Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
  8. Khalili H, Wolpin BM, Huang ES, et al (2011). ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 20, 1017-20. https://doi.org/10.1158/1055-9965.EPI-10-1250
  9. Lee KH, Yoon HS, Choi SJ, Kang D (2009). Asbestos exposure and malignant mesothelioma in Korea. Asian Pac J Cancer Prev, 10, 707-10.
  10. Metintas S, Metintas M, Ucgun I, Oner U (2002). Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest, 122, 2224-9. https://doi.org/10.1378/chest.122.6.2224
  11. Nakao M, Matsuo K, Hosono S, et al (2011). ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci, 102, 1076-80. https://doi.org/10.1111/j.1349-7006.2011.01907.x
  12. Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y (1989). Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with antisurfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol, 20, 53-7. https://doi.org/10.1016/0046-8177(89)90202-5
  13. Peto R, Pike MC, Armitage P, et al (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer, 35, 1-39. https://doi.org/10.1038/bjc.1977.1
  14. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M (2001). Genetic-susceptibility factor and malignant mesothelioma in the cappadocian region of Turkey. Lancet, 357, 444-5. https://doi.org/10.1016/S0140-6736(00)04013-7
  15. Rusch VW, Giroux D, Kennedy C, et al (2012). Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol, 7, 1631-9. https://doi.org/10.1097/JTO.0b013e31826915f1
  16. Stahel RA, Weder W, Lievens Y, et al (2010). Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 126-8. https://doi.org/10.1093/annonc/mdp271
  17. Tanrikulu AC, Abakay A, Kaplan MA, et al (2010). A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration, 80, 480-7. https://doi.org/10.1159/000321370
  18. Tischoff I, Neid M, Neumann V, Tannapfel A (2011). Pathohistological diagnosis and differential diagnosis. Recent Results Cancer Res, 189, 57-78. https://doi.org/10.1007/978-3-642-10862-4_5
  19. Treasure T, Lang-Lazdunski L, Waller D, et al (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol, 12, 763-72. https://doi.org/10.1016/S1470-2045(11)70149-8
  20. Tsao AS, Wistuba I, Roth JA, Kindler HL (2009). Malignant pleural mesothelioma. J Clin Oncol, 27, 2081-90. https://doi.org/10.1200/JCO.2008.19.8523
  21. Utkan G, Buyukcelik A, Yalcin B, et al (2006). Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer, 53, 367-74. https://doi.org/10.1016/j.lungcan.2006.04.014
  22. Baris YI, Sahin AA, Ozesmi M, et al (1978). An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax, 33, 181-92. https://doi.org/10.1136/thx.33.2.181
  23. Ben Q, Wang K, Yuan Y, Li Z (2011). Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer, 128, 1179-86. https://doi.org/10.1002/ijc.25426
  24. Berman DW, Crump KS (2008). A meta-analysis of asbestosrelated cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol, 38, 49-73. https://doi.org/10.1080/10408440802273156
  25. Carbone M, Baris YI, Bertino P, et al (2011). Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci USA, 108, 13618-23. https://doi.org/10.1073/pnas.1105887108
  26. De Rienzo A, Tor M, Sterman DH, et al (2002). Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem, 84, 455-9. https://doi.org/10.1002/jcb.10058
  27. Aird I, Bentall HH, Roberts JA (1953). A relationship between cancer of stomach and the ABO blood groups. Br Med J, 1, 799-801. https://doi.org/10.1136/bmj.1.4814.799
  28. Annese V, Minervini M, Gabbrielli A, Gambassi G, Manna R (1990). ABO blood groups and cancer of the pancreas. Int J Pancreatol, 6, 81-8.
  29. Dogan AU, Baris YI, Dogan M, et al (2006). Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res, 66, 5063-8. https://doi.org/10.1158/0008-5472.CAN-05-4642
  30. Elkiran ET, Kaplan MA, Sevinc A, et al (2012). Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol, 29, 3147-54. https://doi.org/10.1007/s12032-012-0276-y
  31. Emri S, Demir A, Dogan M, et al (2002). Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol Lett, 127, 251-7. https://doi.org/10.1016/S0378-4274(01)00507-0
  32. Engin H, Bilir C, Ustun H, Gokmen A (2012). ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac J Cancer Prev, 13, 131-3. https://doi.org/10.7314/APJCP.2012.13.1.131
  33. Greer JB, Yazer MH, Raval JS, et al (2010). Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol, 16, 5588-91. https://doi.org/10.3748/wjg.v16.i44.5588
  34. Heintz NH, Janssen-Heininger YM, Mossman BT (2010). Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol, 42, 133-9. https://doi.org/10.1165/rcmb.2009-0206TR
  35. Hosoi E (2008). Biological and clinical aspects of ABO blood group system. J Med Invest, 55, 174-82. https://doi.org/10.2152/jmi.55.174
  36. Husain AN, Colby TV, Ordonez NG, et al (2009). Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med, 133, 1317-31.
  37. Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB (2010). ABO blood group and cancer. Eur J Cancer, 46, 3345-50. https://doi.org/10.1016/j.ejca.2010.08.009
  38. Jordon D, Jagirdar J, Kaneko M (1989). Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol, 135, 931-7.

Cited by

  1. ABO Blood Groups are Not Associated with Treatment Response and Prognosis in Patients with Local Advanced Non-Small Cell Lung Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3945
  2. Relationship Between Prognosis and Neutrophil: Lymphocyte and Platelet:Lymphocyte Ratios in Patients with Malignant Pleural Mesotheliomas vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2061
  3. Significance of ABO-Rh Blood Groups in Response and Prognosis in Breast Cancer Patients Treated with Radiotherapy and Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4055
  4. The clinicopathological characteristics with long-term outcomes in malignant mesothelioma vol.31, pp.10, 2014, https://doi.org/10.1007/s12032-014-0232-0